Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 3/2012

01-03-2012 | Case Report

Multiple organ tuberculosis of lung, pleura, and peritoneum in ankylosing spondylitis during adalimumab therapy

Author: Wan-Hee Yoo

Published in: Rheumatology International | Issue 3/2012

Login to get access

Abstract

A case of multiple organ tuberculosis (TBc) involving lung, pleura, and peritoneum in a 39-year-old man with long-standing ankylosing spondylitis (AS) treated with adalimumab was presented. The relationship between antitumor necrosis factor-α (anti-TNF-α) therapy and TBc was also reviewed. This case illustrates that TBc can develop in multiple organs during adalimumab therapy, and thus, the awareness of serious complications of multiple organs and atypical extrapulmonary pattern of TBc during anti-TNF-α therapy needs to be increased.
Literature
1.
van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC Jr, ATLAS Study Group (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54(7):2136–2146PubMedCrossRef
2.
Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, Dougados M, Géher P, Inman RD, Khan MA, Kvien TK, Leirisalo-Repo M, Olivieri I, Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, Böhm H, van Royen BJ, Braun J (2006) ‘ASsessment in AS’ international working group; European League Against Rheumatism (ASAS/EULAR) recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65(4):442–452PubMedCrossRef
3.
Toussirot E, Streit G, Wendling D (2007) Infectious complications with anti-TNFalpha therapy in rheumatic diseases: a review. Recent Pat Inflamm Allergy Drug Discov 1(1):39–47PubMedCrossRef
4.
Strangfeld A, Listing J (2006) Infection and musculoskeletal conditions: bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol 20(6):1181–1195PubMedCrossRef
5.
Azevedo VF, Parchen C, Coelho SA, Lacerda DC, Hirth CG (2009) Tuberculous myositis in a patient with ankylosing spondylitis treated with adalimumab. Rheumatol Int 29(11):1381–1384PubMedCrossRef
6.
Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15):1098–1104PubMedCrossRef
7.
Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, Eggens U, Distler A, Sieper J (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38(4):499–505PubMedCrossRef
8.
Haibel H, Rudwaleit M, Brandt HC, Grozdanovic Z, Listing J, Kupper H, Braun J, Sieper J (2006) Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 54(2):678–681PubMedCrossRef
9.
Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30(12):2563–2571PubMed
10.
Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48(1):35–45PubMedCrossRef
11.
12.
Rychly DJ, Dipiro JT (2005) Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 25(9):1181–1192PubMedCrossRef
13.
14.
Mohan AK, Coté TR, Block JA, Manadan AM, Siegel JN, Braun MM (2004) Tuberculosis following the use of etarnecept, a tumor necrosis factor inhibitor. Clin Infect Dis 39(3):295–299PubMedCrossRef
15.
Bieber J, Kavanaugh A (2004) Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biological treatments. Rheum Dis Clin North Am 30(2):257–270PubMedCrossRef
16.
Antolín J, Azahara M, Hernández C, Blanco M, Mao L, Cigüenza R (2008) Tuberculous peritonitis after treatment with adalimumab. Scand J Infect Dis 40(8):677–678PubMedCrossRef
17.
Gutiérrez-Macías A, Lizarralde-Palacios E, Martínez-Odriozola P, Miguel-de la Villa F (2007) Tuberculous peritonitis in a patient with rheumatoid arthritis treated with adalimumab. Clin Rheumatol 26(3):452–453PubMedCrossRef
18.
Endean AL, Barry SM, Young-Min SA (2009) Possible miliary tuberculosis during adalimumab therapy with negative gamma-IFN release assays. Rheumatology (Oxford) 48(3):319–320CrossRef
19.
Carmona L, Hernández-García C, Vadillo C, Pato E, Balsa A, González-Alvaro I, Study Group EMECAR (2003) Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 30(7):1436–1439PubMed
20.
Stas P, D’Hoore A, Van Assche G, Geboes K, Steenkiste E, Penninckx F, Rutgeerts P, Vermeire S (2006) Miliary tuberculosis following infliximab therapy for Crohn disease: a case report and review of the literature. Acta Gastroenterol Belg 69(2):217–220PubMed
21.
Pai M, Zwerling A, Menzies D (2008) Systematic review: T-cell based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149(3):177–184PubMed
22.
Ferrara G, Losi M, D’Amico R, Roversi P, Piro R, Meacci M, Meccugni B, Dori IM, Andreani A, Bergamini BM, Mussini C, Rumpianesi F, Fabbri LM, Richeldi L (2006) Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 367(9519):1328–1334PubMedCrossRef
Metadata
Title
Multiple organ tuberculosis of lung, pleura, and peritoneum in ankylosing spondylitis during adalimumab therapy
Author
Wan-Hee Yoo
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 3/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1357-x

Other articles of this Issue 3/2012

Rheumatology International 3/2012 Go to the issue

Original Article

Enthesitis and its relationships with disease parameters in Moroccan patients with ankylosing spondylitis

Original Article

Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice

Original Article

FDG-PET in the Erdheim–Chester disease: its diagnostic and follow-up role

Original Article

A PTPN22 promoter polymorphism −1123G>C is associated with RA pathogenesis in Chinese

Original Article

The clinical significance of HRCT in evaluation of patients with rheumatoid arthritis-associated interstitial lung disease: a report from China

Letter to the Editor

A potential explanation of the reported low prevalence of hepatitis B virus infection in patients with systemic lupus erythematosus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits